Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $18.44 USD
Change Today +0.36 / 1.99%
Volume 243.1K
VIVO On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).

meridian bioscience inc (VIVO) Snapshot

Open
$18.12
Previous Close
$18.08
Day High
$18.45
Day Low
$17.91
52 Week High
08/19/14 - $20.60
52 Week Low
01/2/15 - $15.56
Market Cap
769.2M
Average Volume 10 Days
306.5K
EPS TTM
$0.86
Shares Outstanding
41.7M
EX-Date
07/30/15
P/E TM
21.4x
Dividend
$0.80
Dividend Yield
4.34%
Current Stock Chart for MERIDIAN BIOSCIENCE INC (VIVO)

meridian bioscience inc (VIVO) Related Bloomberg News

View More Bloomberg News

meridian bioscience inc (VIVO) Related Businessweek News

No Related Businessweek News Found

meridian bioscience inc (VIVO) Details

Meridian Bioscience Inc., an integrated life science company, manufactures, develops, sells, and distributes diagnostic test kits. These are used primarily for respiratory, gastrointestinal, viral, and parasitic infectious diseases. It also makes and distributes bulk antigens, antibodies, and reagents used by researchers and other diagnostic manufacturers. In addition, it contract-manufactures proteins and other biologicals for biopharmaceutical and biotechnology companies researching new drugs and vaccines. Its products and technologies are marketed to hospitals, reference labs, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in about 60 countries. Meridian, founded in 1976, is based in Cincinnati.

550 Employees
Last Reported Date: 12/1/14
Founded in 1976

meridian bioscience inc (VIVO) Top Compensated Officers

Chairman of The Board, Chief Executive Office...
Total Annual Compensation: $602.9K
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $263.3K
Executive Vice President of Operations and In...
Total Annual Compensation: $408.9K
President of Meridian Bioscience Europe and M...
Total Annual Compensation: $356.7K
Executive Vice President and President of Mer...
Total Annual Compensation: $307.0K
Compensation as of Fiscal Year 2014.

meridian bioscience inc (VIVO) Key Developments

Meridian Bioscience, Inc. Declares Regular Quarterly Cash Dividend for the Third Quarter Ended June 30, 2015, Payable on August 13, 2015; Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended June 30, 2015; Provides Earnings Guidance for the Fiscal Year Ending September 30, 2015

The Board of Directors of Meridian Bioscience, Inc. declared the regular quarterly cash dividend of $0.20 per share for the third quarter ended June 30, 2015. The dividend is of record August 3, 2015 and payable August 13, 2015. The company reported unaudited earnings results for the third quarter and nine months ended June 30, 2015. For the quarter, the company reported net revenues of $48,204,000 against $47,212,000 a year ago. Operating income was $14,398,000 against $13,132,000 a year ago. Earnings before income taxes were $14,305,000 against $12,880,000 a year ago. Net earnings were $9,102,000 or $0.22 per basic and diluted share against $8,835,000 or $0.21 per basic and diluted share a year ago. The third quarter was another solid quarter with reported revenues increasing 2% to $48.2 million despite foreign currency headwinds that negatively impacted revenues by approximately $1.5 million. For the nine months, the company reported net revenues of $147,762,000 against $142,140,000 a year ago. Operating income was $42,799,000 against $40,424,000 a year ago. Earnings before income taxes were $41,925,000 against $40,424,000 a year ago. Net earnings were $27,073,000 or $0.64 per diluted share against $26,561,000 or $0.63 per diluted share a year ago. For the fiscal year ending September 30, 2015, management expects net revenues to be in the range of $193 million to $200 million and per share diluted earnings to be between $0.85 and $0.91. The per share estimates assume an increase in average diluted shares outstanding from approximately 41.9 million at fiscal 2014 year end to approximately 42.4 million at fiscal 2015 year end. The revenue and earnings guidance provided in this press release is from expected internal growth and does not include the impact of any acquisitions the company might complete during fiscal 2015.

Meridian Bioscience, Inc. to Report Q3, 2015 Results on Jul 23, 2015

Meridian Bioscience, Inc. announced that they will report Q3, 2015 results Pre-Market on Jul 23, 2015

Meridian Bioscience Receives FDA Clearance for New Molecular Amplification Test, illumigene® HSV 1&2

Meridian Bioscience, Inc. announced that it has received FDA clearance for two new molecular assays for the detection of Herpes Simplex Virus Type 1 (HSV-1) and Type 2 (HSV-2), to be run on its illumigene® molecular platform. The illumigene® HSV 1&2 assays, launched earlier 2015 in Europe, are now available immediately in the US – they are the eighth and ninth assays added to the illumigene® molecular menu now that includes; C. difficile, Group A Streptococcus, Group B Streptococcus, Mycoplasma, Pertussis, Chlamydia and Gonorrhea. illumigene® HSV 1&2 assays utilize loop-mediated isothermal DNA amplification (LAMP) technology for the qualitative detection and differentiation of HSV-1 and HSV-2 in cutaneous and mucocutaneous specimens. The test procedure is remarkably simple, highly sensitive and provides results in less than one hour. The illumigene platform does not require expensive capital equipment or costly annual service contracts. The performance and simplicity of this technology, along with its cost efficiency and small footprint, make these new assays ideal for enabling a more rapid diagnosis in a moderately complex laboratory setting.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VIVO:US $18.44 USD +0.36

VIVO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ERBA Diagnostics Inc $1.93 USD +0.01
GenMark Diagnostics Inc $8.83 USD -0.27
Luminex Corp $17.81 USD +0.38
Quidel Corp $21.88 USD -0.51
T2 Biosystems Inc $14.11 USD +0.30
View Industry Companies
 

Industry Analysis

VIVO

Industry Average

Valuation VIVO Industry Range
Price/Earnings 21.5x
Price/Sales 3.9x
Price/Book 4.7x
Price/Cash Flow 21.4x
TEV/Sales 3.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MERIDIAN BIOSCIENCE INC, please visit www.meridianbioscience.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.